December 2025 in “Dermatology The American Medical Journal” JAK inhibitors are effective for long-term management of alopecia areata.
Alopesi tedavisinde ilaçlar saç büyümesini teşvik eder ve yeni yaklaşımlar umut vaat eder.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
Baricitinib effectively regrows hair in severe alopecia areata cases.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
July 2025 in “Current Treatment Options in Oncology” Scalp cooling helps prevent hair loss during chemotherapy, and minoxidil aids regrowth.
July 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Microneedling can effectively promote hair regrowth in alopecia areata.
July 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.
April 2025 in “PharmacoEconomics - Open” Patients with Alopecia Areata are willing to trade life duration for better quality of life.
March 2025 in “SKIN The Journal of Cutaneous Medicine” The study within the ALLEGRO clinical trial program assessed 832 patients with alopecia areata (AA) to identify predictors of long-term scalp hair regrowth following ritlecitinib treatment. Key predictors for achieving a SALT score ≤20 at 24 months included baseline SALT score, SALT score at Month 6, non-AT/AU type, duration of AA since diagnosis, and duration of significant scalp hair loss at baseline. These findings indicate that certain patient characteristics can predict treatment outcomes, which may help optimize treatment decisions for AA. However, the predictive models are not yet validated for clinical practice and should not replace professional medical judgment.
Frontal fibrosing alopecia can be managed with personalized combination therapies, but no cure exists yet.
January 2025 in “Bright Sky Publications eBooks” Aesthetic medicine is rapidly advancing with new technologies for safer, personalized, and less invasive treatments.
January 2025 in “Universidad de Córdoba Insitutional Repository (Universidad de Córdoba)” An imbalanced scalp microbiome may worsen alopecia areata severity and inflammation, but treatment can partially restore balance.
December 2024 in “Cureus” Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
July 2024 in “Egyptian Journal of Medical Human Genetics” These gene variations are not linked to alopecia areata in Egyptians.
July 2024 in “Forum Dermatologicum” Topical treatments for hair loss can be effective but need careful safety evaluation.
April 2024 in “Medical & clinical research” More research is needed to find the best long-term treatments for Alopecia Areata.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
April 2024 in “Frontiers in physiology” Immune cells are crucial for hair growth and preventing hair loss.
Hair product allergies are common, especially to hair dyes, and hairdressers are at higher risk.
April 2024 in “Academic dermatology” Dermatologists should carefully manage hair loss in cancer patients to improve their quality of life.
March 2024 in “Dermatology and therapy” AA patients with comorbid conditions face more severe hair loss and need specific treatments.
March 2024 in “Research Square (Research Square)” Scalp cooling therapy helps preserve hair during chemotherapy for most patients.
February 2024 in “International neuropsychiatric disease journal” Alopecia areata severely impacts quality of life, mental health, and work productivity.